CRISPR technology draws mounting interest from investors

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

In a single year, Rodger Novak’s gene-editing startup raised $89 million in venture funding, got $105 million to enter a partnership with big drugmaker Vertex Pharmaceuticals Inc. — and, this week, announced a deal with Bayer AG worth $335 million.

Crispr Therapeutics Ltd. won’t start human trials of its therapies until 2017, but the company is at the forefront of one of the hottest technologies in biotech. Investors and drugmakers from Johnson & Johnson to Merck & Co. are flocking to a potent tool called Crispr, saying its precise DNA editing capabilities could yield treatments for conditions as diverse as blood diseases, cancers, auto-immune disorders and genetic eye disorders.

Gene-editing companies have drawn more than $1 billion in venture dollars since 2013, according to Boston Consulting Group, from traditional biotech venture capitalists like Deerfield Management Co. and Polaris Partners, and names better known in in the tech world, such as Bill Gates and Khosla Ventures. Demand to participate in Crispr Therapeutics’ funding round was so strong that the company turned away some blue-chip investors, Novak said in an interview.

ADVERTISEMENT

Like many promising new technologies that came before it, Crispr has yet to prove it will be effective at creating new medicine. And the idea of editing genes has made some ethicists queasy, though the companies getting funding aren’t making alterations in human sperm, eggs or embryos, which would be controversial.

Read full, original post: The Gene-Editing Tool on Every Drugmaker’s Wish List This Year

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Here’s where GM crops are grown around the world today

Infographic: Here’s where GM crops are grown around the world today

Do you know where biotech crops are grown in the world? This updated ISAAA infographics show where biotech crops were ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists
Send this to a friend